Latest Breaking News On - Blueprint for action national academy of sciences - Page 6 : comparemela.com

Emmaus Life Sciences Real World Data on Endari® Accepted for E-Poster at the 62nd Annual Scientific Meeting of the British Society for Haematology

/PRNewswire/ Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease,.

Ad daw ahUnited statesUnited kingdomFrench guianaRanda alokkaGylna lokoMaryse etienne julanMohamed yassinAhmad adelNarcisse elengaResearch publicationsCenters for diseaseCommittee on addressing sickle cell diseasePrnewswire emmaus life sciences incNational centre for cancer careDrug administration

Emmaus Life Sciences Data on Endari® Accepted for Poster Presentation at the 63rd American Society of Hematology Annual Meeting & Exhibition

/PRNewswire/ Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease,.

United statesGeorgia world congress centerYutaka niiharaMichael callaghanJosephm becerraResearch publicationsCenters for diseaseCommittee on addressing sickle cell diseasePrnewswire emmaus life sciences incDrug administrationEmmaus medical incGmms holdingsAmerican society of hematologyDivision of hematology oncologyNational center on birth defectsBlueprint for action national academy of sciences

Emmaus Life Sciences Enters into Agreement with Asembia to Provide Expanded Patient Support Services

/PRNewswire/ Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease,.

United statesLawrence ireneYutaka niiharaGeorge sekulichCenters for diseaseCommittee on addressing sickle cell diseasePrnewswire emmaus life sciences incDrug administrationNational center on birth defectsBlueprint for action national academy of sciencesEmmaus life sciencesEmmaus life sciences incLife sciencesChief executive officerSenior vice presidentGlobal commercialization

Emmaus Life Sciences Submits Application for U A E Marketing Authorization for Endari®

/PRNewswire/ Emmaus Life Sciences, Inc. (OTC: EMMA) a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today.

Ministry of healthUnited arab emiratesUnited statesYutaka niiharaGeorge sekulichCenters for diseaseCommittee on addressing sickle cell diseasePrnewswire emmaus life sciences incDrug administrationGulf cooperation councilExchange commissionU ae ministry of healthNational center on birth defectsBlueprint for action national academy of sciencesEmmaus life sciencesEmmaus life sciences inc

Emmaus Life Sciences Announces Bahrain Temporary License of Endari®

Emmaus Life Sciences Announces Bahrain Temporary License of Endari®
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Saudi arabiaUnited statesKingdom of bahrainYutaka niiharaGeorge sekulichCenters for diseaseProducts regulation departmentCommittee on addressing sickle cell diseasePrnewswire emmaus life sciences incDrug administrationExchange commissionNational center on birth defectsBlueprint for action national academy of sciencesNational health regulatory authorityEmmaus life sciencesEmmaus life sciences inc